Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Shares Issued (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Shares Issued for 16 consecutive years, with -$484000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued fell 130.67% year-over-year to -$484000.0, compared with a TTM value of $2.1 million through Sep 2025, down 75.84%, and an annual FY2024 reading of $7.7 million, down 24.96% over the prior year.
  • Shares Issued was -$484000.0 for Q4 2025 at Amicus Therapeutics, down from $339000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $19.2 million in Q1 2021 and bottomed at -$12.5 million in Q2 2021.
  • Average Shares Issued over 5 years is $1.6 million, with a median of $1.2 million recorded in 2024.
  • The sharpest move saw Shares Issued skyrocketed 215.95% in 2021, then tumbled 207.68% in 2023.
  • Year by year, Shares Issued stood at $1.8 million in 2021, then crashed by 146.61% to -$859000.0 in 2022, then skyrocketed by 381.02% to $2.4 million in 2023, then crashed by 34.63% to $1.6 million in 2024, then plummeted by 130.67% to -$484000.0 in 2025.
  • Business Quant data shows Shares Issued for FOLD at -$484000.0 in Q4 2025, $339000.0 in Q3 2025, and $40000.0 in Q2 2025.